Study to Compare the Bioavailability of Omeprazole 20 mg Before and After Undergoing Surgery for Morbid Obesity
Status:
Completed
Trial end date:
2016-02-29
Target enrollment:
Participant gender:
Summary
The principal aim was to evaluate whether gastric bypass surgery modifies the bioavailability
of omeprazole 20 mg at one month and six months after surgery.
Other objectives were:
- To compare bioavailability of omeprazole 20 mg between patients undergo gastric bypass
surgery and patients who avoid it.
- To asses other pharmacokinetic parameters, demographic parameters and drug safety.
Study design It was planned a mixed design which intended to compare the bioavailability in
patients with gastric bypass (before and after surgery) and control subjects matched by sex
and body mass index (BMI) post-surgery. This was a single-dose, open-label, crossover
bioavailability study of omeprazole in surgical group and controls.